SRPIN340 inhibits serine-arginine-rich protein kinase 1 (SRPK1), exhibiting antiviral, anti-angiogenic, and anticancer chemotherapeutic activities. In vitro, SRPIN340 inhibits replication of hepatitis C virus (HCV). In animal models of melanoma, this compound decreases expression of VEGF and suppresses tumor growth. SRPIN340 also prevents pathological retinal neovascularization in vivo.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.